A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid, sodium and potassium excretion in healthy subjects.

BMC Pharmacol Toxicol · 2014 · PMC3903027 · PMID 24460668

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients administered 15 g/day CLP lost significantly more weight, had a higher proportion of improvement in New York Heart Association (NYHA) class and showed a trend for improvement in both the six minute walk test and the Kansas City Cardiomyopathy Questionnaire compared to patients receiving placebo [ 13 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.